These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34667923)

  • 1. Recombinant factor IX-Fc fusion protein in severe hemophilia B: Patient-reported outcomes and health-related quality of life.
    O'Donovan M; Quinn E; Johnston K; Singleton E; Benson J; O'Mahony B; Noone D; Duggan C; Gilmore R; Ryan K; O'Donnell JS; O'Connell NM; Mahlangu J
    Res Pract Thromb Haemost; 2021 Oct; 5(7):e12602. PubMed ID: 34667923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B:
    Astermark J; Hermans C; Ezzalfani M; Sidhom A; Barbier S; Kragh N; Falk A; Eriksson D
    Ther Adv Hematol; 2023; 14():20406207231170701. PubMed ID: 37283819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Effectiveness of rFIXFc Prophylaxis in Patients with Haemophilia B Switched from Standard Half-Life Therapy in Three European Countries.
    Funding E; Lowe G; Poulsen LH; Shapiro S; Oldenburg J; Eriksson D; Falk A; Rich C
    Adv Ther; 2023 Sep; 40(9):3770-3783. PubMed ID: 37351812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow-up in a national adult cohort.
    O'Donovan M; Bergin C; Quinn E; Singleton E; Roche S; Benson J; Bird R; Byrne M; Duggan C; Gilmore R; Ryan K; O'Donnell JS; O'Connell NM
    Haemophilia; 2021 Jul; 27(4):618-625. PubMed ID: 33939224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years.
    Shapiro A; Chaudhury A; Wang M; Escobar M; Tsao E; Barnowski C; Feng J; Jain N; Quon DV
    Haemophilia; 2020 Nov; 26(6):975-983. PubMed ID: 33012060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: Post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires.
    Astermark J; Hermans C; Ezzalfani M; Aballéa S; Santagostino E; Hakimi Z; Nazir J
    Haemophilia; 2022 Jan; 28(1):18-26. PubMed ID: 34761474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of extended half-life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B.
    Sun HL; Yang M; Poon MC; Lee A; Robinson KS; Sholzberg M; Wu J; Iorio A; Blanchette V; Carcao M; Klaassen RJ; Jackson S
    Res Pract Thromb Haemost; 2021 Oct; 5(7):e12601. PubMed ID: 34667922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand.
    Álvarez-Román MT; Shapiro AD; Ragni MV; Palmborg H; Bystrická L; Szamosi J; Casiano S; Chambost H
    Res Pract Thromb Haemost; 2023 Aug; 7(6):102163. PubMed ID: 37720484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor product utilization and health outcomes in patients with haemophilia A and B on extended half-life concentrates: A Canadian observational study of real-world outcomes.
    Sun HL; Yang M; Poon MC; Lee A; Robinson KS; Sholzberg M; Wu J; Iorio A; Blanchette V; Carcao M; Klaassen RJ; Jackson S
    Haemophilia; 2021 Sep; 27(5):751-759. PubMed ID: 34160870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.
    Powell JS; Pasi KJ; Ragni MV; Ozelo MC; Valentino LA; Mahlangu JN; Josephson NC; Perry D; Manco-Johnson MJ; Apte S; Baker RI; Chan GC; Novitzky N; Wong RS; Krassova S; Allen G; Jiang H; Innes A; Li S; Cristiano LM; Goyal J; Sommer JM; Dumont JA; Nugent K; Vigliani G; Brennan A; Luk A; Pierce GF;
    N Engl J Med; 2013 Dec; 369(24):2313-23. PubMed ID: 24304002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.
    Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
    J Med Econ; 2017 Apr; 20(4):337-344. PubMed ID: 27885871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A survey of physicians' treatment switching practice in people on long-term prophylaxis for hemophilia in five European countries.
    van der Sluijs M; Huyghe N; Wood C; Tawil S
    Curr Med Res Opin; 2022 Jan; 38(1):65-73. PubMed ID: 34634979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study.
    Fischer K; Kulkarni R; Nolan B; Mahlangu J; Rangarajan S; Gambino G; Diao L; Ramirez-Santiago A; Pierce GF; Allen G
    Lancet Haematol; 2017 Feb; 4(2):e75-e82. PubMed ID: 28159192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.
    Toby GG; Liu T; Buyue Y; Zhang X; Bitonti AJ; Pierce GF; Sommer JM; Jiang H; Peters RT
    PLoS One; 2016; 11(2):e0148255. PubMed ID: 26840952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B.
    Pasi KJ; Fischer K; Ragni M; Nolan B; Perry DJ; Kulkarni R; Ozelo M; Mahlangu J; Shapiro AD; Baker RI; Bennett CM; Barnes C; Oldenburg J; Matsushita T; Yuan H; Ramirez-Santiago A; Pierce GF; Allen G; Mei B
    Thromb Haemost; 2017 Feb; 117(3):508-518. PubMed ID: 28004057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials.
    Astermark J; Wojciechowski P; Aballéa S; Hakimi Z; Nazir J; Klamroth R
    J Blood Med; 2021; 12():613-621. PubMed ID: 34285621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single centre, real-world experience of perioperative rFIXFc use in adult patients with haemophilia B undergoing major and minor surgery.
    O'Donovan M; Singleton E; Roche S; McGowan M; Benson J; Bergin C; Bird R; Byrne M; Duggan C; Gilmore R; Ryan K; Dougall A; O'Donnell JS; O'Connell NM
    Haemophilia; 2021 Nov; 27(6):e690-e697. PubMed ID: 34614282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates.
    Powell J; Shapiro A; Ragni M; Negrier C; Windyga J; Ozelo M; Pasi J; Baker R; Potts J; Li S; Mei B; Pierce GF; Robinson B
    Br J Haematol; 2015 Jan; 168(1):113-23. PubMed ID: 25209873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study.
    Pasi KJ; Fischer K; Ragni M; Kulkarni R; Ozelo MC; Mahlangu J; Shapiro A; P'Ng S; Chambost H; Nolan B; Bennett C; Matsushita T; Winding B; Fruebis J; Yuan H; Rudin D; Oldenburg J
    Haemophilia; 2020 Nov; 26(6):e262-e271. PubMed ID: 32497409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of rFIXFc versus N9-GP Prophylaxis in Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PARADIGM 2 Trials.
    Mancuso ME; Eriksson D; Falk A; Hakimi Z; Wojciechowski P; Wdowiak M; Klamroth R
    J Blood Med; 2023; 14():427-434. PubMed ID: 37534261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.